Ropes & Gray represented Sanofi and EQT Life Sciences in their investment in SpliceBio’s $135 million Series B financing. SpliceBio is a Barcelona-based clinical-stage genetic medicines company with a proprietary protein splicing platform. The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease.
The Ropes & Gray team included venture capital and emerging companies counsel David Dowling, IP transactions partner Melissa Rones, IP transactions counsel Ryan Murphey, strategic transactions associate Jennifer Eppinger, and venture capital and emerging companies partner Rajarshi Banerjee.